565835

3AC

≥98% (1H-NMR), solid, SHIP1 inhibitor, Calbiochem^®

• Synonyme(s) : SHIP1 Inhibitor, 3AC, 3α-Aminocholestane, SH2-domain-containing inositol 5ʹ-phosphatase 1 (SHIP1) Inhibitor, 3AC
• Formule empirique (notation de Hill): C₂₇H₄₉N
• Poids moléculaire : 387.68
• Code UNSPSC : 12352200
• Nomenclature NACRES : NA.77

Propriétés

• product name: SHIP1 Inhibitor, 3AC, The SHIP1 Inhibitor, 3AC controls the biological activity of SHIP1. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
• Niveau de qualité: 100
• Pureté: ≥98% (¹H-NMR)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze
• Couleur: white
• Solubilité: ethanol: 100 mg/mL; DMSO: insoluble
• Conditions d'expédition: ambient
• Température de stockage: 2-8°C

Description

Description générale

A cell-permeable steroidal compound that selectively inhibits SHIP1′ polyphosphatase activity toward PI(3,4,5)P3 (IC₅₀ = 10 µM), but not SHIP2 5′ or PTEN′ polyphosphatase activity toward PI(3,4,5)P3 (IC₅₀ >1 mM). Effectively inhibits SHIP1-mediated immune response both in vitro and in vivo, as well as SHIP1-dependent cancer cell survival. SHIP2 Inhibitor, AS1938909 is also available (Cat. No. 565840).

A cell-permeable steroidal compound that selectively inhibits SHIP1-, but not SHIP2-, catalyzed PI(3,4,5)P3-to-PI(3,4)P2 dephosphorylation (IC₅₀ = 10 µM vs. >1 mM, respectively), while exhibiting little activity against the PTEN-catalyzed PI(3,4,5)P3-to-PI(4,5)P2 conversion (IC₅₀ >1 mM). 3AC in vivo treatment (2.292 umol/200 µl/mouse/daily i.p. for 7 d) is reported to boost both peripheral blood granulocyte production (by 4- to 5-fold) and the GVHD- (graft-versus-host disease) suppressing Mac1⁺Gr1⁺ MIR (myeloid immunoregulatory) cell population in lymphoid tissues (by 5.55- and 11.53-fold in spleen and lymph nodes, respectively), resulting in an impaired splenocyte allogeneic T cell response in MLR (mixed-leukocyte/lymphocyte reaction) assays (by ≥95%). Similarly, 3AC-treated (9.4 µM; 24 h) primary human PBMCs greatly lose their ability in priming allogeneic T cell response in MLR assays (by 74.5%). In addition, a faster blood cell recovery is also observed in mice receiving 3AC (2.292 umol/200 µl/mouse/daily i.p. for 7 d) after sub-lethal irradiation (550 Rads). Selectively inhibits the growth and survival of SHIP1-dependent human KG-1 and murine C1498 myelogenous leukemia lines (IC₅₀ = 11.5 µM), but not the SHIP1-negative human CML K562 and osteosarcoma MG63 lines. SHIP2 Inhibitor, AS1938909 is also available (Cat. No. 565840).

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Autres remarques

Brooks, R., et al. 2010. J. Immunol.184, 3582.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 2
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable